AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 24451221 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported disease behavior for Crohn's disease
Number of subjects: 450
Study 24451221 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported disease location for ulcerative colitis
Number of subjects: 450
Study 24451221 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported history of bowel surgery for Crohn's disease
Number of subjects: 450
Study 24451221 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported history of bowel surgery for ulcerative colitis
Number of subjects: 450
Study 24451221 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported current pouch or ostomy for Crohn's disease
Number of subjects: 450
Study 24451221 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported current pouch or ostomy for ulcerative colitis
Number of subjects: 450
Study 22348468 — intervention group
Group type: EXPERIMENTAL
Intervention: DHA-enriched fish oil supplement (250 mg DHA/d and 60 mg EPA/d)
Number of subjects: 420
Study 22348468 — intervention group
Group type: EXPERIMENTAL
Intervention: DHA-enriched fish oil supplement
Number of subjects: 420
Study 22348468 — intervention group
Group type: COMPARATOR
Intervention: Placebo (olive oil)
Number of subjects: 420
Study 20947710 — intervention group
Group type: EXPERIMENTAL
Intervention: Double poling at low intensity (∼53% Vo(2peak))
Number of subjects: 8
Study 20947710 — intervention group
Group type: EXPERIMENTAL
Intervention: Double poling at high intensity (∼74% Vo(2peak))
Number of subjects: 8
Study 17629042 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab (5 mg/kg) at 0, 2, and 6 weeks, then every 8 weeks
Number of subjects: 24
Study 17629042 — intervention group
Group type: COMPARATOR
Intervention: Methylprednisolone (0.8-1 mg/kg daily for 3 weeks, then tapering)
Number of subjects: 24
Study 16266385 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal budesonide (100 microg per nostril)
Number of subjects: 32
Study 16266385 — intervention group
Group type: COMPARATOR
Intervention: Matched placebo
Number of subjects: 32
Study 11904593 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-sampling methods (swabs and tampons)
Number of subjects: 103
Study 11904593 — intervention group
Group type: COMPARATOR
Intervention: Clinician-directed sampling (speculum sampling)
Number of subjects: 103
Study 11904593 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-sampling methods (2 sequential swabs)
Number of subjects: 103
Study 11904593 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-sampling methods
Number of subjects: 103
Study 10935831 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced glutathione (GSH) 600 mg intramuscularly for 12 weeks
Number of subjects: 32
Study 10935831 — intervention group
Group type: COMPARATOR
Intervention: Symptomatic therapies for 12 weeks
Number of subjects: 32
Study 8548221 — intervention group
Group type: EXPERIMENTAL
Intervention: Subtotal colectomy
Number of subjects: 91
Study 8548221 — intervention group
Group type: COMPARATOR
Intervention: On-table irrigation and segmental colectomy
Number of subjects: 91
Study 2021388 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose intramuscular triamcinolone (360 mg over the first three days)
Number of subjects: 12
Study 2021388 — intervention group
Group type: COMPARATOR
Intervention: Low-dose oral prednisone (median dose 12.5 mg per day)
Number of subjects: 12
Study 2021388 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose intramuscular triamcinolone
Number of subjects: 12
Study 6302831 — intervention group
Group type: EXPERIMENTAL
Intervention: pivmecillinam 200 mg t.i.d. for 1 week
Number of subjects: 15
Study 31806543 — intervention group
Group type: EXPERIMENTAL
Intervention: Denosumab (120 mg) subcutaneously every 3-4 weeks for about 6 months, then every 12 weeks for a total duration of 5 years.
Number of subjects: 4509
Study 31806543 — intervention group
Group type: COMPARATOR
Intervention: Placebo subcutaneously every 3-4 weeks for about 6 months, then every 12 weeks for a total duration of 5 years.
Number of subjects: 4509
Study 31806543 — intervention group
Group type: EXPERIMENTAL
Intervention: Denosumab
Number of subjects: 4509
Study 31806543 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4509
Study 31329023 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-factor gradual self-control group
Number of subjects: 60
Study 31329023 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-controlled task difficulty group
Number of subjects: 60
Study 31329023 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-controlled feedback group
Number of subjects: 60
Study 31329023 — intervention group
Group type: COMPARATOR
Intervention: Yoked conditions (control)
Number of subjects: 60
Study 28270286 — intervention group
Group type: EXPERIMENTAL
Intervention: Third-generation dual-source CT scanner (collimation of 2×192×0.6 mm, rotation time of 0.25 s)
Number of subjects: 59
Study 28270286 — intervention group
Group type: COMPARATOR
Intervention: Second-generation dual-source CT scanner (collimation of 2×128×0.6 mm, rotation time of 0.28 s)
Number of subjects: 59
Study 26265678 — intervention group
Group type: EXPERIMENTAL
Intervention: Birth weight (BW) for estimating UVC insertion depth
Number of subjects: 188
Study 26265678 — intervention group
Group type: COMPARATOR
Intervention: Shoulder-umbilicus length for estimating UVC insertion depth
Number of subjects: 188
Study 26265678 — intervention group
Group type: EXPERIMENTAL
Intervention: Birth weight (BW) for estimating UAC insertion depth
Number of subjects: 188
Study 26265678 — intervention group
Group type: COMPARATOR
Intervention: Shoulder-umbilicus length for estimating UAC insertion depth
Number of subjects: 188
Study 26634615 — intervention group
Group type: EXPERIMENTAL
Intervention: ICG-guided antihypertensive therapy
Number of subjects: 272
Study 26634615 — intervention group
Group type: COMPARATOR
Intervention: Empiric antihypertensive therapy
Number of subjects: 272
Study 23663796 — intervention group
Group type: EXPERIMENTAL
Intervention: 30‐min lumbar massage by a physiotherapist during the active phase of labour
Number of subjects: 46
Study 23663796 — intervention group
Group type: COMPARATOR
Intervention: Control group (physiotherapist only answered questions)
Number of subjects: 46
Study 22005661 — intervention group
Group type: EXPERIMENTAL
Intervention: Subepineural injection at the neural bifurcation
Number of subjects: 50
Study 22005661 — intervention group
Group type: COMPARATOR
Intervention: Separate postbifurcation injections around the tibial and peroneal nerves
Number of subjects: 50
Study 19126874 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistant maltodextrin (RMD) 6 g in drinks
Number of subjects: 37
Study 19126874 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistant maltodextrin (RMD) 6 g in solid foods
Number of subjects: 37
Study 19126874 — intervention group
Group type: COMPARATOR
Intervention: Placebo drinks and foods (control)
Number of subjects: 37
Study 16881811 — intervention group
Group type: EXPERIMENTAL
Intervention: Customized interdental brushing technique
Number of subjects: 77
Study 16881811 — intervention group
Group type: COMPARATOR
Intervention: Customized flossing technique
Number of subjects: 77
Study 15592308 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol 200 mug
Number of subjects: 20
Study 15592308 — intervention group
Group type: COMPARATOR
Intervention: Methylergometrine 250 mug
Number of subjects: 20
Study 11352438 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasted condition (moxifloxacin 400mg)
Number of subjects: 18
Study 11352438 — intervention group
Group type: COMPARATOR
Intervention: Fed condition (moxifloxacin 400mg)
Number of subjects: 18
Study 11398591 — intervention group
Group type: COMPARATOR
Intervention: Multifrequency bioimpedance spectroscopy analysis (BIS)
Number of subjects: 360
Study 11398591 — intervention group
Group type: EXPERIMENTAL
Intervention: BIS pre-HD measurements
Number of subjects: 360
Study 11398591 — intervention group
Group type: EXPERIMENTAL
Intervention: BIS post-HD measurements
Number of subjects: 360
Study 11398591 — intervention group
Group type: EXPERIMENTAL
Intervention: BIS measurements
Number of subjects: 360
Study 7625347 — intervention group
Group type: COMPARATOR
Intervention: Standard-phosphorus (215 micrograms/kJ, or 90 mg/100 kcal)
Number of subjects: 35
Study 7625347 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-phosphorus (254 micrograms/kJ, or 106 mg/100 kcal)
Number of subjects: 35
Study 7625347 — intervention group
Group type: EXPERIMENTAL
Intervention: High-phosphorus (287 micrograms/kJ, or 120 mg/100 kcal)
Number of subjects: 35
Study 2165750 — intervention group
Group type: EXPERIMENTAL
Intervention: Formoterol 20 ng
Number of subjects: 0
Study 2165750 — intervention group
Group type: COMPARATOR
Intervention: Terbutaline 500 ng
Number of subjects: 0
Study 2165750 — intervention group
Group type: EXPERIMENTAL
Intervention: Formoterol 0.5 micrograms
Number of subjects: 0
Study 2165750 — intervention group
Group type: COMPARATOR
Intervention: Terbutaline 25 micrograms
Number of subjects: 0
Study 533740 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Exercise (HIE)
Number of subjects: 79
Study 533740 — intervention group
Group type: COMPARATOR
Intervention: Low-Intensity Exercise (LIE)
Number of subjects: 79
Study 31907528 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyunsaturated fat
Number of subjects: 0
Study 31907528 — intervention group
Group type: COMPARATOR
Intervention: Saturated fat
Number of subjects: 0
Study 31325379 — intervention group
Group type: COMPARATOR
Intervention: Low RFI ducks (LRFI)
Number of subjects: 1000
Study 31325379 — intervention group
Group type: COMPARATOR
Intervention: Correlation analysis
Number of subjects: 1000
Study 28912116 — intervention group
Group type: EXPERIMENTAL
Intervention: Tablet-based EORTC QLQ-C30 questionnaire
Number of subjects: 106
Study 28912116 — intervention group
Group type: COMPARATOR
Intervention: Paper-based EORTC QLQ-C30 questionnaire
Number of subjects: 106
Study 26201227 — intervention group
Group type: COMPARATOR
Intervention: Standard adhesion procedure for direct resin composite restorations (Group 1)
Number of subjects: 648
Study 26201227 — intervention group
Group type: EXPERIMENTAL
Intervention: Additional procedure of enamel adhesive on the outer boundary of the finished restoration (Group 2)
Number of subjects: 648
Study 23557413 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimedia program on parasite infestations (cybertutor)
Number of subjects: 50
Study 23557413 — intervention group
Group type: COMPARATOR
Intervention: Standard classes on parasite infestations
Number of subjects: 50
Study 22000938 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 1332
Study 22000938 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine
Number of subjects: 1332
Study 22000938 — intervention group
Group type: EXPERIMENTAL
Intervention: Perphenazine
Number of subjects: 1332
Study 22000938 — intervention group
Group type: EXPERIMENTAL
Intervention: Ziprasidone
Number of subjects: 1332
Study 22000938 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 1332
Study 22000938 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall (across medication phases)
Number of subjects: 1332
Study 22000938 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline
Number of subjects: 1332
Study 19470312 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram (19 patients)
Number of subjects: 72
Study 19470312 — intervention group
Group type: COMPARATOR
Intervention: Placebo (18 patients)
Number of subjects: 72
Study 19470312 — intervention group
Group type: COMPARATOR
Intervention: Citalopram and Placebo (both groups)
Number of subjects: 72
Study 16622703 — intervention group
Group type: EXPERIMENTAL
Intervention: Quick stretch (2 nm per half-sarcomere length) applied to muscle fibers
Number of subjects: 235
Study 14727018 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure Support (PS) ventilation
Number of subjects: 10
Study 14727018 — intervention group
Group type: EXPERIMENTAL
Intervention: Assist-Control/Volume-Targeted (AC/VT) ventilation
Number of subjects: 10
Study 14727018 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing back-up rate to Fmax during PS and AC/VT ventilation
Number of subjects: 10
Study 14727018 — intervention group
Group type: COMPARATOR
Intervention: Spontaneous breathing
Number of subjects: 10
Study 11372180 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific acupuncture sites
Number of subjects: 24
Study 11372180 — intervention group
Group type: COMPARATOR
Intervention: Unspecific sites (control group, placebo acupuncture)
Number of subjects: 24
Study 9234562 — intervention group
Group type: EXPERIMENTAL
Intervention: Transurethral incision of prostate (TUIP) - bilateral incision
Number of subjects: 45
Study 10362410 — intervention group
Group type: EXPERIMENTAL
Intervention: Epinephrine
Number of subjects: 12
Study 10362410 — intervention group
Group type: EXPERIMENTAL
Intervention: Norepinephrine plus dobutamine (5 microg/kg/min)
Number of subjects: 12
Study 10362410 — intervention group
Group type: COMPARATOR
Intervention: Norepinephrine
Number of subjects: 12
Study 2229897 — intervention group
Group type: EXPERIMENTAL
Intervention: Punctum plug treatment on one side
Number of subjects: 35
Study 2229897 — intervention group
Group type: COMPARATOR
Intervention: Placebo (simulation insertion)
Number of subjects: 35
Study 907395 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastric bypass (90% gastric exclusion with Roux-en-Y reconstitution)
Number of subjects: 59
Study 907395 — intervention group
Group type: COMPARATOR
Intervention: Jejunoileal bypass (end-to-end anastomosis between 30 cm of jejunum and 25 cm of terminal ileum)
Number of subjects: 59
Study 30621105 — intervention group
Group type: COMPARATOR
Intervention: ABCG2 rs72552713
Number of subjects: 521
Study 30621105 — intervention group
Group type: COMPARATOR
Intervention: SLC22A12 rs11231825
Number of subjects: 521
Study 30621105 — intervention group
Group type: COMPARATOR
Intervention: rs12505410
Number of subjects: 521
Study 30621105 — intervention group
Group type: COMPARATOR
Intervention: Serum uric acid and systolic blood pressure
Number of subjects: 521
Study 28285255 — intervention group
Group type: EXPERIMENTAL
Intervention: 8h time in bed (TIB) restriction with fluoxetine 20-40 mg
Number of subjects: 30
Study 28285255 — intervention group
Group type: COMPARATOR
Intervention: 6h time in bed (TIB) restriction with fluoxetine 20-40 mg
Number of subjects: 30
Study 28285255 — intervention group
Group type: EXPERIMENTAL
Intervention: 6h time in bed (TIB) restriction with delayed bedtime or advanced risetime
Number of subjects: 30
Study 25417042 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training (IMT) using a pressure threshold device, 5 sessions weekly for 12 weeks, 30 mins/day
Number of subjects: 46
Study 25417042 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 46
Study 23064222 — intervention group
Group type: EXPERIMENTAL
Intervention: BOC/PEG2a/R
Number of subjects: 201
Study 23064222 — intervention group
Group type: COMPARATOR
Intervention: PEG2a/R
Number of subjects: 201
Study 21747291 — intervention group
Group type: EXPERIMENTAL
Intervention: Betaine supplementation (BET) for 15 days
Number of subjects: 11
Study 21747291 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL) for 15 days
Number of subjects: 11
Study 19489257 — intervention group
Group type: EXPERIMENTAL
Intervention: High-pull headgear
Number of subjects: 40
Study 19489257 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 40
Study 16942534 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil (100 mg)
Number of subjects: 132
Study 16942534 — intervention group
Group type: EXPERIMENTAL
Intervention: Vardenafil (20 mg)
Number of subjects: 132
Study 16942534 — intervention group
Group type: EXPERIMENTAL
Intervention: Tadalafil (20 mg)
Number of subjects: 132
Study 16942534 — intervention group
Group type: COMPARATOR
Intervention: Sildenafil (100 mg) vs Tadalafil (20 mg)
Number of subjects: 132
Study 16942534 — intervention group
Group type: COMPARATOR
Intervention: Vardenafil (20 mg) vs Tadalafil (20 mg)
Number of subjects: 132
Study 16942534 — intervention group
Group type: COMPARATOR
Intervention: Tadalafil (20 mg) vs Sildenafil (100 mg)
Number of subjects: 132
Study 16942534 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall treatment
Number of subjects: 132
Study 16942534 — intervention group
Group type: EXPERIMENTAL
Intervention: All drugs
Number of subjects: 132
Study 16281636 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical corticosteroids
Number of subjects: 200
Study 16281636 — intervention group
Group type: EXPERIMENTAL
Intervention: Cosmetics and skin care products
Number of subjects: 200
Study 16281636 — intervention group
Group type: EXPERIMENTAL
Intervention: Atopic diseases history
Number of subjects: 200
Study 16281636 — intervention group
Group type: EXPERIMENTAL
Intervention: Prick test reactivity
Number of subjects: 200
Study 16281636 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific IgE against aeroallergens
Number of subjects: 200
Study 11588133 — intervention group
Group type: COMPARATOR
Intervention: Lung cancer cases (n=356)
Number of subjects: 820
Study 11588133 — intervention group
Group type: COMPARATOR
Intervention: Prostate cancer cases (n=235)
Number of subjects: 820
Study 11588133 — intervention group
Group type: EXPERIMENTAL
Intervention: Subpopulation of prostate cancer patients (n=174)
Number of subjects: 820
Study 9327830 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiplatelet drugs (aspirin, ticlopidine, thromboxane A2 receptor inhibitors)
Number of subjects: 0
Study 9327830 — intervention group
Group type: EXPERIMENTAL
Intervention: Antithrombotics (heparin, hirudin, hirulog)
Number of subjects: 0
Study 9327830 — intervention group
Group type: EXPERIMENTAL
Intervention: ACE inhibitors, HMG‐CoA reductase inhibitors, fish‐oil supplements
Number of subjects: 0
Study 9327830 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiproliferatives (angiopeptin, trapidil, tranilast)
Number of subjects: 0
Study 9327830 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycoprotein IIb/IIIa receptor antagonists, inhibitors of the early coagulation cascade, calcium channel blockers, nitric oxide donors
Number of subjects: 0
Study 8514980 — intervention group
Group type: EXPERIMENTAL
Intervention: octreotide
Number of subjects: 20
Study 8514980 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 20
Study 3716740 — intervention group
Group type: COMPARATOR
Intervention: Gastric bypass
Number of subjects: 57
Study 3716740 — intervention group
Group type: COMPARATOR
Intervention: Gastroplasty
Number of subjects: 57
Study 30590843 — intervention group
Group type: EXPERIMENTAL
Intervention: Eye-lens dosemeters (Dosilab, Landauer, IRSN)
Number of subjects: 90
Study 27355501 — intervention group
Group type: EXPERIMENTAL
Intervention: Active patient follow-up package of interventions including individualized health education, use of flip charts, phone and SMS appointment reminders, active tracking after missed visits, and individualized support.
Number of subjects: 0
Study 27355501 — intervention group
Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 0
Study 24637237 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard smoking-cessation booklet
Number of subjects: 0
Study 24637237 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivation-based booklet designed specifically for USAF personnel
Number of subjects: 0
Study 24637237 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivation-based booklet combined with a brief, face-to-face motivational session
Number of subjects: 0
Study 22493927 — intervention group
Group type: EXPERIMENTAL
Intervention: New moxibustion‐massage apparatus
Number of subjects: 60
Study 22493927 — intervention group
Group type: COMPARATOR
Intervention: Suspended moxibustion
Number of subjects: 60
Study 20061961 — intervention group
Group type: EXPERIMENTAL
Intervention: Mood Spectrum Self‐Report Questionnaire factors 'depressive mood' and 'psychotic features'
Number of subjects: 226
Study 20061961 — intervention group
Group type: EXPERIMENTAL
Intervention: Panic‐Agoraphobic Spectrum Self‐Report Questionnaire factors 'separation anxiety' and 'loss sensitivity'
Number of subjects: 226
Study 20061961 — intervention group
Group type: EXPERIMENTAL
Intervention: Mood Spectrum Self‐Report Questionnaire factor 'psychomotor retardation'
Number of subjects: 226
Study 20061961 — intervention group
Group type: EXPERIMENTAL
Intervention: Panic‐Agoraphobic Spectrum Self‐Report Questionnaire factor 'fear of losing control'
Number of subjects: 226
Study 18548088 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxation therapies
Number of subjects: 1198
Study 16173850 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional Behavioral Couple Therapy (TBCT)
Number of subjects: 134
Study 16173850 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrative Behavioral Couple Therapy (IBCT)
Number of subjects: 134
Study 16173850 — intervention group
Group type: EXPERIMENTAL
Intervention: TBCT
Number of subjects: 134
Study 16173850 — intervention group
Group type: EXPERIMENTAL
Intervention: IBCT
Number of subjects: 134
Study 12592235 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide 10 mg
Number of subjects: 141
Study 12592235 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 141
Study 10099724 — intervention group
Group type: EXPERIMENTAL
Intervention: Portable liquid oxygen therapy (PLOT)
Number of subjects: 30
Study 10099724 — intervention group
Group type: COMPARATOR
Intervention: Compressed air simulating oxygen
Number of subjects: 30
Study 8551199 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 degrees retinal photography
Number of subjects: 663
Study 8551199 — intervention group
Group type: COMPARATOR
Intervention: One 45 degrees field
Number of subjects: 663
Study 8551199 — intervention group
Group type: COMPARATOR
Intervention: Two 45 degrees fields
Number of subjects: 663
Study 8551199 — intervention group
Group type: COMPARATOR
Intervention: Ophthalmologist's assessment
Number of subjects: 663
Study 1879247 — intervention group
Group type: EXPERIMENTAL
Intervention: Colloidal aqueous solution of vitamin E (acetate ester)
Number of subjects: 44
Study 1879247 — intervention group
Group type: COMPARATOR
Intervention: Olive oil solution of vitamin E
Number of subjects: 44
Study 7092487 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenelzine sulfate
Number of subjects: 39
Study 7092487 — intervention group
Group type: EXPERIMENTAL
Intervention: Clorgyline
Number of subjects: 39
Study 7092487 — intervention group
Group type: EXPERIMENTAL
Intervention: Pargyline hydrochloride
Number of subjects: 39
Study 7092487 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated MAO-inhibitor treatment (crossover study of clorgyline and pargyline)
Number of subjects: 39